ReviewIndian journal of ophthalmology2018
Simplifying "target" intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma.
Review in Indian journal of ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 3 syntheses or guidelines pooled it, 174 citations in OpenAlex.
- Advances in glaucoma biomechanics from 2000 to 2024: a bibliometric study and visualization analysis.Frontiers in neuroscience · 2025Pooled it
- The Hippo signalling pathway and its impact on eye diseases.Journal of cellular and molecular medicine · 2024Pooled it
- Meta-Analysis of the Comprehensive Efficacy of Intraocular Lens Implantation in Glaucoma Patients.BioMed research international · 2022Pooled it
- Agreement between intraocular pressure measurement using Goldmann applanation tonometry with and without fluorescein in consecutive Ghanaian patients.Ghana medical journal · 2025Trial
- A Comparative Study of the Clinical Efficacy and Safety of Pneumatic Trabeculoplasty and Selective Laser Trabeculoplasty for Patients with Primary Open-Angle Glaucoma or Ocular Hypertension.Medical science monitor : international medical journal of experimental and clinical research · 2021Trial
- Viscotrabeculotomy versus trabeculectomy in the surgical treatment of open angle glaucoma: a single center, randomised controlled trial.Japanese journal of ophthalmology · 2021Trial
- Evaluation of iStent® Inject W in mild to moderate primary open-angle glaucoma - Indian data on pseudophakic eyes.Indian journal of ophthalmology · 2026Article
- Long-Term Effects of Phacoemulsification with Goniosynechialysis in Angle-Closure Glaucoma: A 2-Year Prospective Cohort Study.Ophthalmology and therapy · 2026Article
- Phacoemulsification combined with bent ab interno needle goniectomy versus high-frequency deep sclerotomy: a comparative study of surgical outcomes in open-angle glaucoma.BMC ophthalmology · 2026Article
- Predictive value of peripheral blood lymphocytes for glaucoma susceptibility: a clinical observational study.BMC ophthalmology · 2026Observational
- Combined phacogoniosynechialysis with viscocanalostomy and Ologen implant for the management of primary angle-closure glaucoma: a retrospective cohort pilot study.BMC ophthalmology · 2026Article
- rAAV prostaglandin-based gene therapy lowers intraocular pressure and preserves optic nerve health in glaucomatous DBA/2J mice.bioRxiv : the preprint server for biology · 2026Article
- Comparison of outcomes of circumferential versus hemi-gonioscopy-assisted transluminal trabeculotomy in primary open-angle glaucoma: 24-Month results.International ophthalmology · 2026Article
- Effect of Combined Cataract and Minimally Invasive Glaucoma Surgeries on Glaucoma-Specific Quality of Life.Journal of clinical medicine · 2026Article
- RNA-binding protein ELAVL1 modulates WDR36 to inhibit p53 pathway and reduce calcium overload in retinal cells under acute pressure elevation.Open life sciences · 2026Article
- Phacoemulsification with IOL implantation combined with goniosynechialysis and goniotomy in primary angle-closure glaucoma following failed trabeculectomy: short-term effectiveness and safety outcomes.Frontiers in medicine · 2026Article
- Comparison of intraocular pressure measurements with and without fluorescein using Goldmann applanation tonometry.Indian journal of ophthalmology · 2026Article
- Short-term outcomes of the PreserFlo MicroShunt in Japanese patients with exfoliation glaucoma: a comparison with primary open-angle glaucoma using propensity score matching.Japanese journal of ophthalmology · 2026Observational
- Ab interno trabeculotomy with vs. without cataract surgery for POAG: a retrospective study.Frontiers in medicine · 2026Article
- Anterior Segment OCT Imaging of Bleb Morphological Changes as Predictors of Success After Bleb Needling.Turkish journal of ophthalmology · 2025Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lowering of intraocular pressure is currently the only therapeutic measure for Glaucoma management. Many longterm, randomized trials have shown the efficacy of lowering IOP, either by a percentage of baseline, or to a specified level. This has lead to the concept of 'Target" IOP, a range of IOP on therapy, that would stabilize the Glaucoma/prevent further visual field loss, without significantly affecting a patient's quality of life. A clinical staging of Glaucoma by optic nerve head evaluation and perimetric parameters, allows a patient's eye to be categorized as having - mild, moderate or severe Glaucomatous damage. An initial attempt should be made to achieve the following IOP range for both POAG or PACG after an iridotomy. In mild glaucoma the initial target IOP range could be kept as 15-17 mmHg, for moderate glaucoma 12-15 mmHg and in the severe stage of glaucomatous damage 10-12 mmHg. Factoring in baseline IOP, age, vascular perfusion parameters, and change on perimetry or imaging during follow up, this range may be reassessed over 6 months to a year. "Target" IOP requires further lowering when the patient continues to progress or develops a systemic disease such as a TIA. Conversely, in the event of a very elderly or sick patient with stable nerve and visual field over time, the target IOP could be raised and medications reduced. An appropriate use of medications/laser/surgery to achieve such a "Target" IOP range in POAG or PACG can maintain visual fields and quality of life, preventing Glaucoma blindness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.